-
Product Insights
NewNet Present Value Model: Simcere Pharmaceutical Group Ltd’s (Borneol + Edaravone)
Empower your strategies with our Net Present Value Model: Simcere Pharmaceutical Group Ltd's (Borneol + Edaravone) report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Simcere Pharmaceutical Group Ltd’s PEG-Endo
Empower your strategies with our Net Present Value Model: Simcere Pharmaceutical Group Ltd's PEG-Endo report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Simcere Pharmaceutical Group Ltd’s (Borneol + Edaravone)
Empower your strategies with our Net Present Value Model: Simcere Pharmaceutical Group Ltd's (Borneol + Edaravone) report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Simcere Pharmaceutical Group Ltd’s AQP-4
Empower your strategies with our Net Present Value Model: Simcere Pharmaceutical Group Ltd's AQP-4 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Botensilimab in Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Botensilimab in Colorectal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Botensilimab in Colorectal Cancer Drug Details: AGEN-1181 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pacmilimab in Bladder Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pacmilimab in Bladder Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pacmilimab in Bladder Cancer Drug Details: CX-072 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Margetuximab in Metastatic Bile Duct Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Margetuximab in Metastatic Bile Duct Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Margetuximab in Metastatic Bile Duct Cancer Drug Details: Margetuximab (Margenza)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (Dexborneol + Edaravone) in Acute Ischemic Stroke
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Dexborneol + Edaravone) in Acute Ischemic Stroke report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (Dexborneol + Edaravone) in Acute Ischemic Stroke Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AGI-134 in Endometrial Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. AGI-134 in Endometrial Cancer Drug Details: AGI-134 is under development for the treatment of solid...
-
Product Insights
Ascites – Drugs In Development, 2023
Global Markets Direct’s, ‘Ascites - Drugs In Development, 2023’, provides an overview of the Ascites pipeline landscape. The report provides comprehensive information on the therapeutics under development for Ascites, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...